Alpha-ketoglutarate (AKG): does it slow aging?
Reviewed 19 sourcesPublished by PepVault
What alpha-ketoglutarate did in worms, mice and people: the 2020 mouse result, the NIA's two nulls, the 8-year Rejuvant claim and the ABLE trial, as of 2026.

- Last reviewed
- Sources
- 19
- Questions
- 8
- Compounds
- 1
The short answer
Not in people, so far. Alpha-ketoglutarate (AKG), a molecule from the cell's energy cycle, lengthened worm life by about half and female mouse life by 10 to 17% in one lab, but the NIA's three-site mouse program found no gain in two tries. The human data are uncontrolled, and the placebo-controlled aging trials, led by ABLE, had not reported by November 2026.
Evidence: Lifespan data are in worms and mice, with one positive mouse study and two null NIA trials; human data are one uncontrolled analysis, one cross-sectional cohort and older small trials, with no aging RCT reported yet.

What is alpha-ketoglutarate?
Alpha-ketoglutarate is one of the steps in the Krebs cycle, the chain of reactions inside mitochondria that turns food into usable energy. Every cell makes it. Its level shifts with fasting, exercise and age1, and the supplement sold for longevity is AKG bound to calcium, called Ca-AKG or CaAKG.
The interest started with a worm. In 2014 a UCLA team found that AKG extended the adult life of the roundworm C. elegans by about 50%2. AKG binds ATP synthase, the cell's main energy-making enzyme, and slows it slightly, which lowers the TOR growth signal and raises autophagy, the cell's recycling of worn parts. Worms make more AKG when starved, and AKG did not lengthen the life of worms already on a restricted diet: it works like a chemical version of eating less2.
One claim to set straight: you will read that human AKG levels fall 10-fold between 40 and 80. The 2020 mouse paper quotes it from a 2008 review114; we found no human study that measured that drop. A 2026 atlas of 12 organs in aging mice did name AKG among the metabolic drivers of aging its organ clocks picked out15.

What did the 2020 mouse study find?
The study behind the supplement came from the Buck Institute. Mice ate a diet that was 2% Ca-AKG by weight from 18 months old, an age when mice already show some signs of aging1. In two separate groups of females, median life from the start of feeding rose by 16.6% and 10.5%. Males lived 9.6% and 12.8% longer on median, but their survival gain was not statistically significant in either group1.
The bigger effect was on health. The team scored 31 signs of frailty, from coat and gait to tumors, through old age. The share of life spent frail fell by 46% in females and 41% in males1. T cells from treated females made more IL-10, an anti-inflammatory signal, which the authors propose as the mechanism; the rise was female-specific1.
Species note: every lifespan result on this page is in worms or mice. Several of the 2020 study's authors held shares in Ponce de Leon Health, the company that sells the AKG formula Rejuvant, and filed a patent on the finding1.
Did other labs repeat the mouse result?
Not yet. The NIA's Interventions Testing Program (ITP) tests each compound at three sites in genetically mixed mice, the stricter design. It tried AKG twice. Started at 18 months, as in the Buck study, AKG gave no lifespan benefit in either sex34. Started at 7 months, it again did nothing: median life moved +3.4% in males and −1.6% in females, neither significant4.
| Study | Animal | What happened |
|---|---|---|
| Chin 2014, UCLA2 | Roundworms | Adult life about 50% longer at the best concentration |
| Asadi Shahmirzadi 2020, Buck1 | One mouse strain, from 18 months | Female median life +16.6% and +10.5%; male +9.6% and +12.8% (survival not significant); frail time −46% females, −41% males |
| ITP, born 20203 | Mixed mice, three sites, from 18 months | No lifespan benefit in either sex |
| ITP, born 20224 | Mixed mice, three sites, from 7 months | Males +3.4%, females −1.6%; neither significant |
One detail limits the second try. In the 2022 cohort the chow was meant to carry 20,000 parts per million of AKG, the Buck study's 2%; the measured amount was 3,262, about a sixth4. So that try tested a far lower dose. The 18-month try, the direct repeat of the Buck design, found none either34.
Does AKG lower biological age in people?
The famous number is 8 years. It comes from a 2021 analysis of 42 customers of Rejuvant, Ponce de Leon Health's formula of 1 g Ca-AKG with vitamin A for men or vitamin D for women5. They were about 63 on average, took it for 4 to 10 months and tested their biological age with a commercial saliva test (a DNA-methylation clock, which reads chemical tags on DNA that change with age) before and after. The average result was 8 years younger5.
There was no placebo group, the people chose how long to take it, and one author sat on the company's board5. A clock that moves 8 years in 7 months, in a test whose error in this cohort was about 4 years5, needs a control group before anyone can say how much of that is AKG.
| Study | Who | Design | Result |
|---|---|---|---|
| Rejuvant users, 20215 | 42 adults, average age 63 | Before and after, no control | Saliva clock age 8 years lower after about 7 months |
| Health-enthusiast cohort, 20266 | 4,260 people who took a commercial saliva clock test | One-time survey and test, no control | Rejuvant takers 1.8 years lower on the clock; plain AKG takers a smaller, non-significant gap |
| Rejuvant placebo trial, NCT048214017 | 100 adults aged 45 to 75 | Randomized, placebo, 9 months; main measure hs-CRP | Completed February 2022; no results posted by November 20, 2026 |
| Bone, 200711 | 76 postmenopausal women with low bone density | Randomized, double-blind, 6 months; 6 g AKG with calcium vs calcium | Bone-breakdown marker CTX down 37% at 24 weeks; spine density gap 0.9%, not significant |
| Heel pressure ulcers, 200912 | 160 adults over 60 | Randomized, placebo, 6 weeks; ornithine-AKG 10 g a day | No difference in ulcer shrinkage; faster closure in ulcers of 8 cm² or less |
The 2026 cohort, from a Singapore team that includes one of ABLE's authors, adds a second hint: people who already took the delayed-release formula scored 1.8 years younger6. Some were recruited through the Rejuvant maker, with free test vouchers6. Its own authors name the limit: people who buy longevity tests and supplements differ in many ways, so only a controlled trial can settle it6. The company's own 100-person placebo trial, which measured inflammation, finished in 2022 and has posted nothing7.
When does the ABLE trial report?
ABLE is the test that counts: 120 healthy adults aged 40 to 60 in Singapore whose DNA-methylation age was older than their real age, given 1 g a day of sustained-release Ca-AKG or a placebo for 6 months, then followed for 3 more89. Neither the volunteers nor the staff know who takes which (double-blind). The main measure is the change in methylation age; strength, arterial stiffness, aerobic fitness and blood inflammation markers are secondary8.
As of November 20, 2026, the registry lists ABLE as active, not recruiting, with its main measure collected by August 15, 2025 and the study due to close on January 15, 2027; no results are posted9. A 2026 paper from the trial shows it ran well: 59 people on AKG and 61 on placebo, average age 50.6, more than 90% of doses taken, 17% dropout10.
| Trial | Size | What it tests | State on Nov 20, 2026 |
|---|---|---|---|
| ABLE, Singapore (NCT05706389)9 | 120 | 1 g a day for 6 months; methylation age | Active, not recruiting; closes January 2027 |
| Shenzhen (NCT07114536)16 | 34 | 2 g a day for 12 weeks; PhenoAge, a blood-test aging score | Completed November 2025; no results posted |
| AEGIS, heart bypass surgery, Singapore (NCT07031128)17 | 250 adults 50 and over | AKG vs placebo around surgery; complications to day 90 | Recruiting (record updated June 2025) |
| Brain aging, Oklahoma (NCT07861867)18 | 60 adults 55 and over | 1 g a day for 24 weeks; brain blood-flow coupling | Not yet recruiting; due 2029 |
| Eye, Stanford (NCT07269704)19 | 17 | 2 g a day for 7 days; AKG level in the eye's fluid | Completed June 2025; no results posted |
What doses did the AKG studies use?
These are the amounts researchers chose and monitored, set out to show what was studied, not a dose for any one person.
| Study | Form | Amount and length |
|---|---|---|
| ABLE8 | Sustained-release Ca-AKG | 1 g a day for 6 months |
| Rejuvant users5 | Ca-AKG monohydrate with vitamin A or D | 1,000 mg a day for 4 to 10 months |
| Shenzhen trial16 | Ca-AKG tablets | 2 g a day for 12 weeks |
| Bone trial11 | AKG with calcium | 6 g AKG and 1.68 g calcium a day for 6 months |
| Pressure ulcer trial12 | Ornithine-AKG | 10 g a day for 6 weeks |
| Buck mouse study1 | Ca-AKG in the chow | 2% of the diet by weight, for life |
Ca-AKG brings calcium with it: one 1,000 mg serving of the Rejuvant formula lists 190 mg of calcium5. That counts toward the calcium from food and any other supplement.
PepVault can hold an oral supplement in grams on a daily schedule, with a dose time and an optional reminder if the day's dose is not logged. Set reminders in PepVault
Does AKG have side effects?
Commonly reported: nothing felt day to day; some people on several grams a day mention an upset stomach.
Published side-effect data at the 1 g longevity dose are thin, because the placebo-controlled trials have not reported. At higher doses the record is calm. In the pressure-ulcer trial, serious events were similar on ornithine-AKG and placebo (15 against 13 people), and none was judged to come from the treatment12. In a small dialysis study using calcium AKG as a phosphate binder, 5 of 17 people stopped in the first two weeks for stomach symptoms such as poor appetite, vomiting or diarrhea; all five had stomach complaints before they started, and the other 12 reported none13.
Kidney disease and medicines that act on calcium or phosphate are the cases where AKG meets a prescription; there the decision is the prescriber's.
So does AKG slow aging?
Here is the evidence by species. In worms it lengthens life through the same switch that eating less flips2. In mice, one lab saw longer, much healthier lives1, and the NIA's stricter program saw no change in two tries34. In people, the numbers so far come from customers and test buyers with no control group56, plus older trials in bone and wound healing that were not about aging1112.
The first real answer is due from ABLE, whose 120 volunteers finish when the study closes in January 20279. Until then, a before-and-after test of your own carries the same weakness as the 8-year claim: without a comparison, the clock's own noise looks like a result.
If you take it, PepVault logs each day's dose, so the months on AKG sit on record beside any test you take before and after. Log it in PepVault
Sources
- Asadi Shahmirzadi A et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metab. 2020. PubMed 32877690
- Chin RM et al. The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014. PubMed 24828042
- Miller RA et al. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. Geroscience. 2024. PubMed 38753230
- Korstanje R et al. Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. Geroscience. 2026. PubMed 41843349
- Demidenko O et al. Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY). 2021. PubMed 34847066
- Pabis K et al. Supplements and drugs are associated with biological age in a cohort of exceptionally healthy individuals. Aging Cell. 2026. PubMed 42166733
- ClinicalTrials.gov NCT04821401. Rejuvant safety and biomarker study (Ponce De Leon Health), accessed November 20, 2026. clinicaltrials.gov
- Sandalova E et al. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE): intervention study protocol. Geroscience. 2023. PubMed 37217632
- ClinicalTrials.gov NCT05706389. Does alpha-ketoglutarate supplementation lower biological age in middle-aged adults? (ABLE, National University of Singapore), accessed November 20, 2026. clinicaltrials.gov
- Lu JK et al. Optimizing accelerometer implementation in a gerotherapeutic trial: feasibility, adherence, and operational insights of ABLE. PLOS Digit Health. 2026. PubMed 42789532
- Filip RS et al. Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX) in postmenopausal women with osteopenia: six-month study. Int J Vitam Nutr Res. 2007. PubMed 17896582
- Meaume S et al. Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial. J Nutr Health Aging. 2009. PubMed 19621198
- Bro S et al. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis. 1998. PubMed 9469496
- Harrison AP, Pierzynowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption/metabolism, muscle performance, kidney function, bone formation and cancerogenesis, all viewed from a healthy ageing perspective. J Physiol Pharmacol. 2008. PubMed 18802218
- Pilley SE et al. A metabolic atlas of mouse aging. Cell Metab. 2026. PubMed 41297544
- ClinicalTrials.gov NCT07114536. Calcium alpha-ketoglutarate supplementation on biological aging, physical performance and health indicators (Shenzhen Hygieia Biotech), accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT07031128. Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS, National University Hospital, Singapore), accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT07861867. AKG and brain health in aging (University of Oklahoma), accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT07269704. Nutritional supplement alpha-ketoglutarate for age-related ocular disease (Stanford University), accessed November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.